Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Equity to Asset 0.63
DXR's Equity to Asset is ranked higher than
51% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. DXR: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
DXR' s Equity to Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.67 Max: 0.87
Current: 0.63
0.47
0.87
Interest Coverage 2.98
DXR's Interest Coverage is ranked lower than
90% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.90 vs. DXR: 2.98 )
Ranked among companies with meaningful Interest Coverage only.
DXR' s Interest Coverage Range Over the Past 10 Years
Min: 3.93  Med: 25.28 Max: 9999.99
Current: 2.98
3.93
9999.99
WACC vs ROIC
1.96%
1.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 61.83
DXR's Operating margin (%) is ranked higher than
98% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. DXR: 61.83 )
Ranked among companies with meaningful Operating margin (%) only.
DXR' s Operating margin (%) Range Over the Past 10 Years
Min: -323.35  Med: -256.19 Max: 281.17
Current: 61.83
-323.35
281.17
Net-margin (%) -403.81
DXR's Net-margin (%) is ranked lower than
93% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. DXR: -403.81 )
Ranked among companies with meaningful Net-margin (%) only.
DXR' s Net-margin (%) Range Over the Past 10 Years
Min: -445.9  Med: -36.59 Max: 858.77
Current: -403.81
-445.9
858.77
ROE (%) -21.48
DXR's ROE (%) is ranked lower than
75% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. DXR: -21.48 )
Ranked among companies with meaningful ROE (%) only.
DXR' s ROE (%) Range Over the Past 10 Years
Min: -62.33  Med: -1.02 Max: 30.74
Current: -21.48
-62.33
30.74
ROA (%) -12.22
DXR's ROA (%) is ranked lower than
71% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. DXR: -12.22 )
Ranked among companies with meaningful ROA (%) only.
DXR' s ROA (%) Range Over the Past 10 Years
Min: -34.68  Med: -0.75 Max: 16.86
Current: -12.22
-34.68
16.86
Revenue Growth (3Y)(%) -2.80
DXR's Revenue Growth (3Y)(%) is ranked lower than
73% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. DXR: -2.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DXR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: 10.10 Max: 28.9
Current: -2.8
-100
28.9
» DXR's 10-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

DXR Guru Trades in Q4 2014

Jim Simons 48,500 sh (+2.11%)
» More
Q1 2015

DXR Guru Trades in Q1 2015

Jim Simons 50,700 sh (+4.54%)
» More
Q2 2015

DXR Guru Trades in Q2 2015

Jim Simons 51,100 sh (+0.79%)
» More
Q3 2015

DXR Guru Trades in Q3 2015

Jim Simons 52,700 sh (+3.13%)
» More
» Details

Insider Trades

Latest Guru Trades with DXR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.53
DXR's P/B is ranked higher than
69% of the 256 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.31 vs. DXR: 1.53 )
Ranked among companies with meaningful P/B only.
DXR' s P/B Range Over the Past 10 Years
Min: 0.62  Med: 1.07 Max: 2.55
Current: 1.53
0.62
2.55
P/S 24.16
DXR's P/S is ranked lower than
99.99% of the 255 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. DXR: 24.16 )
Ranked among companies with meaningful P/S only.
DXR' s P/S Range Over the Past 10 Years
Min: 14  Med: 26.51 Max: 71.17
Current: 24.16
14
71.17
EV-to-EBIT 40.86
DXR's EV-to-EBIT is ranked lower than
82% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.49 vs. DXR: 40.86 )
Ranked among companies with meaningful EV-to-EBIT only.
DXR' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.6  Med: 1.40 Max: 62.5
Current: 40.86
-12.6
62.5
EV-to-EBITDA 40.86
DXR's EV-to-EBITDA is ranked lower than
86% of the 222 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.03 vs. DXR: 40.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
DXR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13  Med: 1.40 Max: 62.5
Current: 40.86
-13
62.5
Shiller P/E 9.83
DXR's Shiller P/E is ranked higher than
95% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 36.32 vs. DXR: 9.83 )
Ranked among companies with meaningful Shiller P/E only.
DXR' s Shiller P/E Range Over the Past 10 Years
Min: 8.09  Med: 13.32 Max: 92.65
Current: 9.83
8.09
92.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.52
DXR's Dividend Yield is ranked lower than
85% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.43 vs. DXR: 0.52 )
Ranked among companies with meaningful Dividend Yield only.
DXR' s Dividend Yield Range Over the Past 10 Years
Min: 0.34  Med: 4.51 Max: 14.53
Current: 0.52
0.34
14.53
Dividend Growth (3y) -68.90
DXR's Dividend Growth (3y) is ranked lower than
89% of the 54 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.20 vs. DXR: -68.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
DXR' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: -51.9
Current: -68.9
Forward Dividend Yield 0.52
DXR's Forward Dividend Yield is ranked lower than
84% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.43 vs. DXR: 0.52 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.52
DXR's Yield on cost (5-Year) is ranked lower than
100% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. DXR: 0.52 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
DXR' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.34  Med: 4.51 Max: 14.53
Current: 0.52
0.34
14.53
3-Year Average Share Buyback Ratio 1.20
DXR's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.00 vs. DXR: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DXR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.9  Med: 1.10 Max: 6.1
Current: 1.2
-3.9
6.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.53
DXR's Price/Tangible Book is ranked higher than
78% of the 239 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.36 vs. DXR: 1.53 )
Ranked among companies with meaningful Price/Tangible Book only.
DXR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.8  Med: 1.70 Max: 2.76
Current: 1.53
0.8
2.76
Price/Median PS Value 0.85
DXR's Price/Median PS Value is ranked higher than
66% of the 256 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.13 vs. DXR: 0.85 )
Ranked among companies with meaningful Price/Median PS Value only.
DXR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.46  Med: 1.34 Max: 9.13
Current: 0.85
0.46
9.13
Earnings Yield (Greenblatt) (%) 2.44
DXR's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. DXR: 2.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DXR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 34.70 Max: 107414.6
Current: 2.44
1.6
107414.6

More Statistics

Revenue(Mil) $1
EPS $ -0.25
Beta0.09
Short Percentage of Float0.48%
52-Week Range $5.40 - 9.18
Shares Outstanding(Mil)3.90

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Daxor Corp was originally incorporated in New York State as Iatric Corporation in May 1971for cryobanking services and continues these services through its wholly-owned subsidiary, Scientific Medical Systems. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May 1973, the name Idant Corporation was changed to Daxor Corporation. It is a medical device manufacturing Company, which offers additional biotech services, such as cryobanking, through its wholly owned subsidiary Scientific Medical Systems Corp. The main focus of the Company has been the development and marketing of an instrument that rapidly and accurately measures human blood volume. This instrument is used in conjunction with a single use diagnostic injection and collection kit that the Company also sells to its customers. The Company's main focus has been on the development of the BVA-100(r) Blood Volume Analyzer, an instrument that rapidly and accurately measures human blood volume. The instrument is used in conjunction with Volumex(r), a single-use radiopharmaceutical diagnostic injection and collection kit. The BVA-100 has also been used to aid in the diagnosis and treatment of polycythemia, hypertension, anemia, chronic fatigue, and to aid in presurgical evaluation. Additional possible uses include management of kidney dialysis, ultrafiltration, and blood optimization for elective surgery. The Company's marketing of the blood volume analyzer could be divided roughly into three phases: initial beta testing at local facilities, late-stage beta testing at nationally recognized institutions - with an emphasis on developing studies for publication, and marketing of the instrument for clinical use. During late-stage beta testing and the marketing phase, the instrument continued to experience a number of major technical improvements and alternations. It competes for customers based on a variety of factors, including reputation, customer service, performance, expertise, price and scope of service offerings.
» More Articles for DXR

Headlines

Articles On GuruFocus.com
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Weekly 3-Year Low Stocks: PBR, NJ, DWA, DXR Feb 10 2013 
Daxor Corp Reports Operating Results (10-Q) Nov 12 2010 
Daxor Corp Reports Operating Results (10-Q) Aug 13 2010 
Daxor Corp Reports Operating Results (10-Q) May 11 2010 
Daxor Corp Reports Operating Results (10-Q) Nov 12 2009 
Daxor Corp Reports Operating Results (10-Q) Aug 13 2009 
Daxor Corp Reports Operating Results (10-Q) May 12 2009 

More From Other Websites
Daxor Corporation Announces Sale of BVA-100 Blood Volume Analyzer to Nebraska Medicine Feb 08 2016
Technical Data Drives the Market - Analyst Review of Orkla, Magic Software Enterprises, Iao Kun... Jan 29 2016
Daxor Corporation Announces an Increased Dividend and the Appointment of Michael Feldschuh as... Dec 10 2015
Daxor Corporation Announces an Increased Dividend and the Appointment of Michael Feldschuh as... Dec 10 2015
Daxor Corporation Announces Filing of Form N-Q for September 30, 2015 Nov 30 2015
Daxor Corporation Announces Filing of Form N-Q for September 30, 2015 Nov 27 2015
Second Heart Failure Study from the Mayo Clinic Utilizing Daxor’s BVA-100 Blood Volume Analyzer... Nov 25 2015
Second Heart Failure Study From the Mayo Clinic Utilizing Daxor's BVA-100 Blood Volume Analyzer... Nov 25 2015
Heart Failure Research from the Mayo Clinic Utilizing the BVA-100 Blood Volume Analyzer presented at... Oct 02 2015
Heart Failure Research From the Mayo Clinic Utilizing the BVA-100 Blood Volume Analyzer Presented at... Oct 01 2015
Taglich Brothers Initiates Coverage of Daxor Corporation Sep 04 2015
Daxor Corporation, a medical instrumentation and biotechnology company, announced today the... Sep 02 2015
Daxor Announces Hire of Senior Vice President, Marketing and Commercial Development Sep 02 2015
Daxor Corporation Announces Filing of Form N-CSR for June 30, 2015 Aug 28 2015
Daxor Corporation Announces Filing of Form N-CSR for June 30, 2015 Aug 28 2015
Daxor Announces an Update on its Stock Buyback Program and Changes in Marketing Aug 13 2015
Daxor Announces an Update on Its Stock Buyback Program and Changes in Marketing Aug 13 2015
Daxor Announces the receipt of a contract for the placement of a BVA-100 Blood Volume Analyzer at... Jun 23 2015
Daxor Announces the Receipt of a Contract for the Placement of a BVA-100 Blood Volume Analyzer at... Jun 23 2015
Daxor Announces the Receipt of a Contract for the Placement of a BVA-100 Blood Volume Analyzer at... Apr 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK